🇺🇸 ABBV-075 in United States

9 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 9

Most-reported reactions

1. Abdominal Pain — 1 report (11.11%)
2. Clostridium Difficile Infection — 1 report (11.11%)
3. Dehydration — 1 report (11.11%)
4. Hepatic Haematoma — 1 report (11.11%)
5. Hyperleukocytosis — 1 report (11.11%)
6. Lung Infection — 1 report (11.11%)
7. Parainfluenzae Virus Infection — 1 report (11.11%)
8. Rash Maculo-Papular — 1 report (11.11%)
9. Stomatitis — 1 report (11.11%)

Source database →

Frequently asked questions

Is ABBV-075 approved in United States?

ABBV-075 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for ABBV-075 in United States?

AbbVie is the originator. The local marketing authorisation holder may differ — check the official source linked above.